United States Therapeutic Plasma Exchange (TPE) Market By Product (Consumables, Devices); By Technology (Centrifugation, Membrane Separation); By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Autoimmune Disorders, Other Indications); By End User (Blood Collection Centres & Blood Component Providers, Hospitals & Transfusion Centres, Other End Users); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Market Analysis, Trends, Opportunity and Forecast, 2023-2032

US Therapeutic Plasma Exchange (TPE) Market Overview and Definition

United States therapeutic plasma exchange (TPE) market is projected to reach USD 320 million by 2032, at a CAGR of 6.5% during the forecast period 2022-2032. According to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases. There has also been a massive rise in the prevalence of various autoimmune disorders in the U.S in the recent years which has led to a surge in research and development activities in the region by the pre-existing and new pharma & biotech companies. A solution which has been emerging in the form of Therapeutic Plasma Exchange has proven to be substantial in treating various kinds of prevailing and rare illnesses in the region and also globally.

Therapeutic Plasma Exchange (TPE) is basically a procedure in which the blood of a patient is made to pass through an apheresis machine, where filtered plasma is removed and is re-infused with fresh red blood cells (RBC) together with replacement fluids, which includes albumin or plasma in patients. Diseases that are treated with the help of therapeutic plasma exchange include acute inflammatory demyelinating polyneuropathy (guillain-barré syndrome), chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis, and thrombotic thrombocytopenic purpura among others.

The U.S is expected to hold the largest share and lead the overall therapeutic plasma exchange systems market due to the increased availability of advanced technology and established healthcare infrastructures in the region. The market is also expected to grow at a more than healthy CAGR in the upcoming years.

US Therapeutic Plasma Exchange (TPE) Market Growth Drivers

The growth of this market is attributed towards major relying factors including; the growing prevalence of neurological and chronic diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory, demyelinating polyneuropathy, and myasthenia gravis, the growing prevalence of multiple sclerosis in the US, growing worldwide population living with numerous disease conditions, rapid and consistent technological progress in this sector in the future years etc.

Moreover, the rising adoption of this form of treatment for the purpose of treating many rare and also prevailing illnesses is likely to offer tremendous scope of growth for players in the US therapeutic plasma exchange market in the years to come.

Furthermore, the therapeutic plasma exchange is adopted  in the treatment of autoimmune, renal, hematological, and hematological diseases with suspected or known immune pathogenesis. Also, this process is being increasingly used in pediatric nephrology, which is likely to foster growth of the US therapeutic plasma exchange market over the years that are to follow in the near future.

More importantly, the Convalescent plasma therapy has been highly successful in treating infected patients with coronavirus lately.  The profound “cytokine storm” induced endotheliopathy and microthrombotic disease in patients with COVID-19 is said to lead to acute respiratory distress syndrome, sepsis, and multi-organ failure. Therapeutic plasma exchange (TPE) is the only known procedure to directly and rapidly decrease plasma viscosity, suggesting that TPE may improve patient outcomes in critically ill patients with COVID-19 by decreasing plasma viscosity and thereby enhancing blood flow. This is contributing massively in augmenting demand and the growth of the overall US TPE market.

However, high cost of apheresis devices and therapeutic plasma exchange procedures, lack of awareness about the TPE process, high installation cost of apheresis devices through a rental model, dearth of skilled professionals, and risks associated with therapeutic plasma exchange procedure are factors that are restraining the growth of this market.

US Therapeutic Plasma Exchange (TPE) Market Regional Synopsis

The US Therapeutic Plasma Exchange (TPE) market can be analyzed through a regional perspective to understand the distribution of this medical procedure across different states and regions within the United States. Regional analysis provides insights into the market dynamics, trends, and opportunities specific to each region. Here is a brief overview of the regional analysis of the US Therapeutic Plasma Exchange market:

Northeast Region: The Northeast region, comprising states such as New York, Massachusetts, Pennsylvania, and New Jersey, is home to several renowned healthcare institutions and research centers. This region has a high demand for advanced medical treatments, including therapeutic plasma exchange. The presence of leading hospitals and a large patient population contributes to the growth of the TPE market in this region.

Midwest Region: The Midwest region, which includes states like Illinois, Ohio, Michigan, and Wisconsin, also exhibits significant market potential for therapeutic plasma exchange. The region has a well-established healthcare infrastructure and a growing number of healthcare facilities offering TPE services. The rising prevalence of autoimmune diseases and other conditions that require TPE contributes to the market growth in this region.

West Region: The West region, consisting of states such as California, Washington, and Oregon, is known for its advanced healthcare systems and strong emphasis on medical research and innovation. The presence of leading medical centers and academic institutions in this region drives the adoption of therapeutic plasma exchange. The West region also has a large population that demands specialized medical treatments, creating opportunities for market growth.

South Region: The South region, including states like Texas, Florida, and Georgia, represents a significant market for therapeutic plasma exchange. The region has a diverse population with a high prevalence of chronic diseases and autoimmune disorders, which often require TPE as part of the treatment regimen.

US Therapeutic Plasma Exchange (TPE) Market Segmentation

By Product

• Consumables
• Devices

By Technology

• Centrifugation
• Membrane Separation

 By Indication

• Neurological Disorders
  • Guillain–Barré syndrome
  • Chronic inflammatory demyelinating polyneuropathy
  • Myasthenia gravis
  • Multiple sclerosis
  • PANDASa 
• Hematology Disorders
  • Thrombotic thrombocytopenic purpura
  • Atypical haemolytic uraemic syndrome
  • Hyperviscosity syndromes
  • Severe/symptomatic Cryoglobulinemia
• Renal Disorders
  • Goodpasture’s syndrome
  • Wegener’s glomerulonephritis
  • Antibody-mediated renal transplant rejection 
• Metabolic Disorders
  • Familial hypercholesterolaemia (homozygous)
• Autoimmune Disorders
• Other Indications

By End User

• Blood Collection Centres & Blood Component Providers
• Hospitals & Transfusion Centres
• Other End Users

Few Key Players in the US Therapeutic Plasma Exchange (TPE) Market

• Terumo BCT Inc.
• Haemonetics Corporation
• Miltenyi Biotec
• Medica S.p.A.
• Medicap Clinic GmbH
• Asahi Kasei Medical Co. Ltd.
• Braun Melsungen AG
• Cerus Corporation
• Infomed
• Fresenius Medical Care
• Baxter International Inc.
• Kawasumi Laboratories Inc.
• Kaneka Corporation
• Nikkiso Co. Ltd.
• HemaCare Corporation
• Other Players

Recent Developments

In November 2020, Cerus Corporation announced that the US Food and Drug Administration (FDA) granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

In December 2020, Spero Therapeutics Inc. a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, announced that its initiation of dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720, Spero’s oral antimicrobial agent in development for the treatment of NTM-PD.

Research Scope and Deliverables

Overview & Executive Summary

Market Drivers, Trends, Challenges and Opportunities

Market Size and Forecast Projections

Macroeconomic Indicators of US Impacting the Growth of the Market

Extensive Coverage of Industry Players including Recent Product Launches and Market Activities

Porter’s Five Force Analysis